Appendix Table 3.
Characteristics Associated with Quality of Buprenorphine Treatment, 2006-2014: Sensitivity Analysis 3
| N of episodes | % of Episodes with Sufficient Duration | Sufficient Duration aOR (95% CI) |
% of Episodes with Effective Dosage | Effective Dosage aOR (95% CI) |
% of Episodes with Concurrent Opioid Analgesics | Concurrent Opioid Analgesics aOR (95% CI) |
% of Episodes with Concurrent Benzodiazepines | Concurrent Benzodiazepines aOR (95% CI) |
|
|---|---|---|---|---|---|---|---|---|---|
| Total | 236,365 | 54.3 | - | 88.4 | - | 26.1 | - | 26.2 | - |
| Age | |||||||||
| 14-25 (omitted) | 39,688 | 49.5 | REF | 87.1 | REF | 20.7 | REF | 19.2 | REF |
| 26-35 | 102,806 | 56.7 | 1.31 (1.28, 1.35) | 89.0 | 1.18 (1.13, 1.22) | 24.9 | 1.27 (1.23, 1.31) | 25.8 | 1.43 (1.38, 1.47) |
| 36-45 | 52,228 | 54.8 | 1.24 (1.20, 1.27) | 89.3 | 1.16 (1.11, 1.21) | 28.5 | 1.45 (1.40, 1.50) | 28.9 | 1.67 (1.61, 1.73) |
| 46-55 | 32,527 | 52.5 | 1.13 (1.09, 1.17) | 88.0 | 1.01 (0.96, 1.06) | 31.1 | 1.50 (1.45, 1.56) | 30.0 | 1.75 (1.68, 1.83) |
| 56-64 | 9,116 | 52.2 | 1.16 (1.10, 1.22) | 84.4 | 0.75 (0.69, 0.80) | 31.5 | 1.47 (1.39, 1.56) | 30.9 | 1.94 (1.82, 2.07) |
| Sex | |||||||||
| Male (omitted) | 100,099 | 52.2 | REF | 89.6 | REF | 23.1 | REF | 23.3 | REF |
| Female | 136,266 | 55.9 | 1.08 (1.05, 1.10) | 87.6 | 0.76 (0.74, 0.79) | 28.2 | 1.23 (1.20, 1.26) | 28.3 | 1.15 (1.12, 1.18) |
| Race/Ethnicity | |||||||||
| Non-Hispanic White (omitted) | 180,668 | 56.3 | REF | 88.8 | REF | 26.0 | REF | 27.4 | REF |
| Non-Hispanic Black | 22,430 | 44.1 | 0.61 (0.59, 0.64) | 86.5 | 0.79 (0.75, 0.83) | 29.2 | 0.84 (0.80, 0.87) | 21.9 | 0.50 (0.48, 0.52) |
| Hispanic | 20,425 | 47.4 | 0.68 (0.66, 0.71) | 88.2 | 0.88 (0.84, 0.93) | 25.5 | 0.86 (0.82, 0.89) | 21.8 | 0.58 (0.55, 0.61) |
| Other/Unknown Race/Ethnicity | 12,842 | 55.5 | 0.95 (0.92, 0.99) | 87.9 | 0.90 (0.84, 0.95) | 22.8 | 0.89 (0.85, 0.93) | 23.7 | 0.76 (0.73, 0.80) |
| Mental Health Comorbidity | |||||||||
| No (omitted) | 113,177 | 46.6 | REF | 87.9 | REF | 20.2 | REF | 14.0 | REF |
| Yes | 123,188 | 61.4 | 1.73 (1.70, 1.76) | 88.9 | 1.16 (1.12, 1.19) | 31.5 | 1.58 (1.55, 1.61) | 37.4 | 3.49 (3.41, 3.57) |
| Chronic Condition | |||||||||
| No (omitted) | 172,419 | 51.7 | REF | 88.3 | REF | 22.3 | REF | 23.4 | REF |
| Yes | 63,946 | 61.3 | 1.59 (1.56, 1.63) | 88.8 | 1.05 (1.02, 1.09) | 36.3 | 1.76 (1.72, 1.80) | 33.8 | 1.35 (1.31, 1.38) |
| Urbanicity | |||||||||
| Metro (omitted) | 185,796 | 52.8 | REF | 88.4 | REF | 25.9 | REF | 26.7 | REF |
| Non-metro, adjacent to urban area | 33,356 | 58.2 | 1.14 (1.11, 1.17) | 87.5 | 1.07 (1.03, 1.12) | 25.7 | 0.97 (0.94, 1.00) | 23.1 | 0.85 (0.82, 0.88) |
| Non-metro, not adjacent to urban area | 17,213 | 62.9 | 1.28 (1.23, 1.33) | 90.1 | 1.29 (1.21, 1.37) | 28.3 | 0.94 (0.90, 0.98) | 26.6 | 0.82 (0.78, 0.86) |
*
Note: All percentages shown in Table 2 represent unadjusted percentages of episodes in each covariate group that met criteria for the dichotomous quality measure. All adjusted models include dichotomous year covariates and state fixed effects, and standard errors clustered at the individual level.